Oliver Luxxe Assets LLC Buys New AstraZeneca Stake
Oliver Luxxe Assets LLC acquired a new AstraZeneca Plc stake in Q2, according to an SEC filing, while Triumph Capital Management also bought a new stake worth $25,000 in Q3. Research coverage remained mixed with several Buy ratings and a few Sell calls. AstraZeneca reported recent quarterly results with $15.38B revenue, 31.45% ROE, and 17.02% net margin.